StockNews.AISignal intelligence
Genmab A/S · NASDAQ · Healthcare
Browse public GMAB signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Genmab’s stock rallied on three October Phase 3 wins, led by petosemtamab with Keytruda. The company is moving to own more of its medicines, funding acquisitions with debt, and expanding commercialization beyond specialist channels. If momentum persists, GMAB could see faster revenue growth and greater royalty leverage as its pipeline matures.
View signal analysisGenmab reported positive LiGeR-HN1 topline results for petosemtamab with Keytruda, showing a 50% reduction in death risk versus pembrolizumab alone in first-line PD-L1+ recurrent/metastatic head and neck cancer, plus higher response rates and no new safety signals. The data could drive global regulatory engagement and expand late-stage opportunities, supporting analyst estimates of up to $8B in peak revenue.
View signal analysisGenmab reported updated Phase 2 results for petosemtamab with pembrolizumab in first-line PD-L1+ r/m HNSCC, delivering a median OS of 28.2 months and an ORR of 63% in 43 efficacy-evaluable patients (CR 19%, mPFS 9.0 months). The Phase 3 program is ongoing, with topline data anticipated later this year, representing a near-term catalyst for GMAB if results validate the Phase 2 signals across HPV+ and HPV- disease.
View signal analysisGenmab's Phase 3 EPCORE DLBCL-1 trial results showed no significant overall survival benefit for epcoritamab against standard chemotherapy, raising concerns regarding its accelerated approval for DLBCL. Despite this, improvements in progression-free survival and other metrics are noted, and analysts still hold a cautiously optimistic view on future trials and potential for market growth.
View signal analysisGenmab's experimental drug for blood cancer failed a late-stage study. This failure may hinder future growth prospects for GMAB.
View signal analysisGenmab discontinues acasunlimab development, focusing on late-stage assets. Analysts previously expected peak sales of $300 million for acasunlimab. Genmab maintains its 2025 financial guidance despite discontinuation. FDA approval received for epcoritamab, enhancing Genmab's position. Potential $8 billion peak sales for three lead assets remains intact.
View signal analysis